

# BILLING AND CODING SUMMARY FOR PHYSICIAN'S OFFICE

**BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).**

The table below provides a brief overview of relevant billing and coding information for BESPONSA, presented in greater detail with the sample CMS-1500 form on the next page.

Item	Coding summary (HCPCS, ICD-10-CM, and CPT®)	Considerations
<b>Drug: BESPONSA</b> <b>(inotuzumab ozogamicin)<sup>1,2</sup></b>  <b>(HCPCS)</b>	<b>Medicare, Medicaid, and commercial payers:</b> <ul style="list-style-type: none"> <li>• J9229 - Injection, inotuzumab ozogamicin, 0.1 mg</li> </ul> Note: Medicare requires the use of the JW modifier (Drug amount discarded/not administered to any patient) when applicable. Other payers' requirements for documenting discarded drug amount, including use of the JW modifier, may vary.	BESPONSA for injection is a white to off-white lyophilized powder supplied in a carton containing one 0.9-mg single-dose vial.  Note: 1 unit of J9229 is 0.1 mg. 1 vial equals 9 units of J9229.
<b>Diagnosis<sup>3</sup></b>  <b>(ICD-10-CM)</b>	<ul style="list-style-type: none"> <li>• C91.00 - Acute lymphoblastic leukemia not having achieved remission</li> <li>OR</li> <li>• C91.01 - Acute lymphoblastic leukemia, in remission</li> <li>OR</li> <li>• C91.02 - Acute lymphoblastic leukemia, in relapse</li> </ul>	Include appropriate ICD-10-CM diagnosis code(s) for patient condition.
<b>Administration<sup>2,4</sup></b>  <b>(CPT®)</b>	<ul style="list-style-type: none"> <li>• 96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug</li> <li>OR</li> <li>• 96415 - Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)</li> </ul>	Include appropriate CPT® code(s) for product administration service(s).  BESPONSA is administered by 1-hour IV infusion on Days 1, 8, and 15 of each 3- to 4-week cycle.  BESPONSA is supplied as a 0.9 mg single-dose vial. Each vial is reconstituted with 4 mL of Sterile Water for Injection, USP, to obtain a concentration of 0.25 mg/mL of BESPONSA.  Please refer to the full Prescribing Information for complete Dosage and Administration instructions.

CPT® is a registered trademark of the American Medical Association.

**Call Pfizer Oncology Together for billing and coding questions at 1-877-744-5675 or visit [www.PfizerOncologyTogether.com](http://www.PfizerOncologyTogether.com)**

The information provided in this document is intended for informational purposes only, and is not a comprehensive description of potential coding requirements for BESPONSA. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and accurate and appropriate coding for treatment of his/her own patients. The information provided in this section should not be considered a guarantee of coverage or reimbursement for BESPONSA.

## SELECTED IMPORTANT SAFETY INFORMATION

**WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY (NRM):**

- Hepatotoxicity, including fatal and life-threatening VOD, occurred in patients who received BESPONSA. The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment. The use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin  $\geq$  upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD
- Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles
- Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice
- There was a higher post-HSCT non-relapse mortality rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate

Please see Important Safety Information on page 3. Please [click here](#) to see full Prescribing Information, including BOXED WARNING, for BESPONSA.



# CMS-1500 FOR PHYSICIAN'S OFFICE<sup>5</sup>

## HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

PICA										PICA	
1. MEDICARE <input type="checkbox"/> MEDICAID <input type="checkbox"/> TRICARE <input type="checkbox"/> CHAMPVA <input type="checkbox"/> GROUP HEALTH PLAN <input type="checkbox"/> FECA BLK LUNG <input type="checkbox"/> OTHER <input type="checkbox"/>				1a. INSURED'S I.D. NUMBER (For Program in Item 1)							
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)				3. PATIENT'S BIRTH DATE MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		4. INSURED'S NAME (Last Name, First Name, Middle Initial)			
5. PATIENT'S ADDRESS (No., Street)				6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>		7. INSURED'S ADDRESS (No., Street)					
CITY				STATE		CITY				STATE	
ZIP CODE				TELEPHONE (Include Area Code)		ZIP CODE				TELEPHONE (Include Area Code)	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)				10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO		11. INSURED'S POLICY GROUP OR FECA NUMBER					
a. OTHER INSURED'S POLICY OR GROUP NUMBER				a. INSURED'S DATE OF BIRTH MM DD YY		SEX M <input type="checkbox"/> F <input type="checkbox"/>		b. RESERVED FOR NUCC USE			
b. RESERVED FOR NUCC USE				c. RESERVED FOR NUCC USE		d. INSURANCE PLAN NAME OR PROGRAM NAME		e. RESERVED FOR NUCC USE			
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize this claim, I also request payment of government benefits below.)				13. OTHER DATE QUAL. MM DD YY		16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY		18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES			
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY				17. NAME OF REFERRING PROVIDER OR OTHER SOURCE		17a. NPI		17b. NPI			
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)				21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E)		ICD Ind.		23. PRIOR AUTHORIZATION NUMBER			
A. _____ B. _____ C. _____ D. _____				E. _____ F. _____ G. _____ H. _____		I. _____ J. _____ K. _____ L. _____		24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY			
B. PLACE OF SERVICE				C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER		E. DIAGNOSIS POINTER		F. \$ CHARGES	
24B. _____				24C. _____		24D. _____		24E. _____		24F. _____	
24G. _____				24H. _____		24I. _____		24J. _____		24K. _____	
24L. _____				24M. _____		24N. _____		24O. _____		24P. _____	
24Q. _____				24R. _____		24S. _____		24T. _____		24U. _____	
24V. _____				24W. _____		24X. _____		24Y. _____		24Z. _____	
24AA. _____				24AB. _____		24AC. _____		24AD. _____		24AE. _____	
24AF. _____				24AG. _____		24AH. _____		24AI. _____		24AJ. _____	
24AK. _____				24AL. _____		24AM. _____		24AN. _____		24AO. _____	
24AP. _____				24AQ. _____		24AR. _____		24AS. _____		24AT. _____	
24AU. _____				24AV. _____		24AW. _____		24AX. _____		24AY. _____	
24AZ. _____				24BA. _____		24BB. _____		24BC. _____		24BD. _____	
24BE. _____				24BF. _____		24BG. _____		24BH. _____		24BI. _____	
24BJ. _____				24BK. _____		24BL. _____		24BM. _____		24BN. _____	
24BO. _____				24BP. _____		24BQ. _____		24BR. _____		24BS. _____	
24BT. _____				24BU. _____		24BV. _____		24BW. _____		24BX. _____	
24BY. _____				24BZ. _____		24CA. _____		24CB. _____		24CC. _____	
24CD. _____				24CE. _____		24CF. _____		24CG. _____		24CH. _____	
24CI. _____				24CJ. _____		24CK. _____		24CL. _____		24CM. _____	
24CN. _____				24CO. _____		24CP. _____		24CQ. _____		24CR. _____	
24CS. _____				24CT. _____		24CU. _____		24CV. _____		24CW. _____	
24CX. _____				24CY. _____		24CZ. _____		24DA. _____		24DB. _____	
24DD. _____				24DE. _____		24DF. _____		24DG. _____		24DH. _____	
24DI. _____				24DJ. _____		24DK. _____		24DL. _____		24DM. _____	
24DN. _____				24DO. _____		24DP. _____		24DQ. _____		24DR. _____	
24DS. _____				24DT. _____		24DU. _____		24DV. _____		24DW. _____	
24DX. _____				24DY. _____		24DZ. _____		24EA. _____		24EB. _____	
24EC. _____				24ED. _____		24EE. _____		24EF. _____		24EG. _____	
24EH. _____				24EI. _____		24EJ. _____		24EK. _____		24EL. _____	
24EM. _____				24EN. _____		24EO. _____		24EP. _____		24EQ. _____	
24ER. _____				24ES. _____		24ET. _____		24EU. _____		24EV. _____	
24EW. _____				24EX. _____		24EY. _____		24EZ. _____		24FA. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____		24FL. _____	
24FM. _____				24FO. _____		24FP. _____		24FQ. _____		24FR. _____	
24FS. _____				24FT. _____		24FU. _____		24FV. _____		24FW. _____	
24FX. _____				24FY. _____		24FZ. _____		24GA. _____		24GB. _____	
24FC. _____				24FD. _____		24FE. _____		24GF. _____		24GG. _____	
24FH. _____				24FI. _____		24FJ. _____		24FK. _____			

## INDICATION

BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

## IMPORTANT SAFETY INFORMATION

**WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY (NRM):**

- Hepatotoxicity, including fatal and life-threatening VOD, occurred in patients who received BESPONSA. The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment. The use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin  $\geq$  upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD
- Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles
- Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice
- There was a higher post-HSCT non-relapse mortality rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate

**Hepatotoxicity, Including Hepatic VOD:** Hepatotoxicity, including fatal and life-threatening VOD, occurred in 23/164 patients (14 %) during or following treatment with BESPONSA or following subsequent HSCT. VOD was reported up to 56 days after the last dose during treatment or follow-up without an intervening HSCT. The median time from HSCT to onset of VOD was 15 days.

Patients with prior VOD or serious ongoing liver disease are at an increased risk of worsening liver disease, including development of VOD, following treatment with BESPONSA. Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites. For patients proceeding to HSCT, the recommended duration of treatment with BESPONSA is 2 cycles. A third cycle may be considered for patients who do not achieve a CR or CRi and MRD-negativity after 2 cycles. Monitor liver tests closely during the first month post HSCT, then less frequently thereafter, according to standard medical practice.

Grade 3/4 increases in aspartate aminotransferase, alanine aminotransferase, and total bilirubin occurred in 7/160 (4 %), 7/161 (4 %), and 8/161 (5 %) patients, respectively.

**Increased Risk of Post-HSCT Non-Relapse Mortality (NRM):** There was a higher post-HSCT NRM rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate. The rate of post-HSCT NRM was 31/79 (39 %) with BESPONSA and 8/35 (23 %) with investigator's choice of chemotherapy. In the BESPONSA arm, the most common causes of post-HSCT NRM included VOD and infections. Monitor closely for toxicities post HSCT, including signs and symptoms of infection and VOD.

**Myelosuppression:** Myelosuppression, and severe, life-threatening, and fatal complications of myelosuppression, including hemorrhagic events and infections, have occurred with BESPONSA. Thrombocytopenia and neutropenia were reported in 83/164 patients (51 %) and 81/164 patients (49 %), respectively. Febrile neutropenia was reported in 43/164 patients (26 %).

Monitor complete blood counts prior to each dose of BESPONSA and monitor for signs and symptoms of infection, bleeding/hemorrhage, or other effects of myelosuppression during treatment and provide appropriate management. As appropriate, administer prophylactic anti-infectives during and after treatment with BESPONSA. Dose interruption, dose reduction, or permanent discontinuation may be required.

**Infusion-Related Reactions:** Infusion-related reactions (all Grade 2) were reported in 4/164 patients (2 %). Premedicate with a corticosteroid, antipyretic, and antihistamine prior to dosing. Monitor patients closely during and for at least 1 hour after the end of the infusion for the potential onset of infusion-related reactions including symptoms such as fever, chills, rash, or breathing problems. Interrupt the infusion and institute appropriate medical management if an infusion-related reaction occurs. Depending on the severity, consider discontinuation of the infusion or administration of steroids and antihistamines. For severe or life-threatening infusion reactions, permanently discontinue BESPONSA.

**QT Interval Prolongation:** Increases in QT interval corrected for heart rate using Fridericia's formula of  $\geq 60$  msec from baseline were measured in 4/162 patients (3 %). Administer BESPONSA with caution in patients who have a history of or predisposition to QTc prolongation, who are taking medicinal products that are known to prolong QT interval, and in patients with electrolyte disturbances. Obtain electrocardiograms and electrolytes prior to treatment and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

**Embryo-Fetal Toxicity:** BESPONSA can cause embryo-fetal harm. Advise pregnant women of the potential risk to the fetus. Advise males and females of reproductive potential to use effective contraception during BESPONSA treatment and for at least 5 and 8 months after the last dose, respectively. Advise women to contact their healthcare provider if they become pregnant or if pregnancy is suspected during treatment with BESPONSA.

**Adverse Reactions:** The most common ( $\geq 20$  %) adverse reactions observed with BESPONSA were thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, and hyperbilirubinemia. The most common ( $\geq 2$  %) serious adverse reactions were infection, febrile neutropenia, hemorrhage, abdominal pain, pyrexia, VOD, and fatigue.

**Nursing Mothers:** Advise women against breastfeeding while receiving BESPONSA and for 2 months after the last dose.

Please [click here](#) to see the full Prescribing Information, including BOXED WARNING, for BESPONSA.

**References:** 1. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/Coding/HCPSCReleaseCodeSets/Alpha-Numeric-HCPCS-Items/2016-Alpha-Numeric-HCPCS-File.html>. Accessed May 2, 2017. 2. BESPONSA Prescribing Information. New York, NY: Pfizer Inc. 3. Centers for Medicare & Medicaid Services website. *ICD-10-CM Tabular List of Diseases and Injuries*. <https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-GEMs.html>. Accessed May 2, 2017. 4. Hollmann PA, et al, eds. *Current Procedural Terminology*. 4th rev ed. Chicago, IL: American Medical Association; 2015. 5. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/downloads/cms1500.pdf>. Accessed May 2, 2017.